Arcelis™ Personalized Immunotherapy Platform

Arcelis is a fully personalized immunotherapy technology that recognizes each individual’s unique disease by capturing mutated and variant antigens, which is capable of triggering a T-cell response specific to the patient’s disease. It is designed to overcome tumor and disease induced immunosuppression in cancer and infectious diseases by eliciting a durable memory T cell response, without commonly used adjuvants in other immunotherapy approaches that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized, cell-based immunotherapies.

The Arcelis process uses only a small tumor or blood sample along with the patient’s own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient’s disease sample (e.g., serves as the antigen payload) to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient’s plasma and administered via intradermal injection.

AGS-003, which is being evaluated in the ADAPT Phase 3 clinical study, is the most advanced Arcelis product candidate. This ongoing global study is designed to examine the potential for AGS-003 plus standard targeted drug therapy to extend overall survival versus standard therapy alone in newly diagnosed patients with unfavorable risk metastatic renal cell carcinoma (mRCC). For more information about AGS-003 and the ADAPT study, visit www.ADAPTkidneycancer.com

Argos has a significant intellectual property estate generated by its scientific leadership in the immunotherapy field. The Company’s patents and patent applications are directed to one or more aspects of the Arcelis technology platform or Arcelis-based products. Specifically, these patents and patent applications are collectively directed to:
• Arcelis-based compositions of matter and products;
• Methods of manufacturing Arcelis-based products;
• Methods of using Arcelis-based products for treatment of tumors; and
• Equipment intended to be used for the automated manufacture of Arcelis-based products.

Argos believes that all of the above aspects of the Arcelis technology platform are required to successfully produce Arcelis-based product candidates and are covered by a combination of the Company’s patents, patent applications, trade secrets and know-how.